# RMAT

First Inhaled Gene Therapy for Lung Cancer Wins FDA Fast‑Track Nod, Raising Hopes — and Questions

An inhaled gene therapy targeting lung cancer has shown promising early clinical efficacy and received FDA RMAT designation and fast‑track status. The move accelerates regulatory review but leaves open critical questions about safety, durability, manufacturing and who will ultimately benefit.